Figure 1.

Ability of celecoxib to inhibit proliferation and enhance the chemosensitivity of Jurkat and Hut-78 cells to anticancer drugs. (A) The inhibition effect of celecoxib on Jurkat and Hut-78 cells for 24, 48 and 72 h was determined. (B) The chemotherapy drugs CDDP, epirubicin and VCR dose-dependently inhibited T-cell lymphoma cells proliferation over 24 h. Cells treated with celecoxib were more sensitive to chemotherapy drugs. (C) IC₅₀ values of CDDP, epirubicin and VCR were decreased in Jurkat and Hut-78 cells treated with celecoxib (P<0.05). (D) Effect of celecoxib on T cells was determined. The viability of normal T cells (control) was not reduced following treatment with celecoxib compared with those without celecoxib treatment. Cell viability and IC₅₀ values are presented as the mean ± standard deviation from three independent experiments. *P<0.05 and **P<0.01 vs. the control group. CDDP, cis-diamminedichloroplatinum; VCR, vinblastine; IC₅₀, half maximal inhibitory concentration.